XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totaling 19,218 shares, a decrease of 97.2% from the April 30th total of 680,467 shares. Based on an average daily volume of 239,726 shares, the short-interest ratio is presently 0.1 days. Currently, 1.2% of the shares of the company are short sold.
XTL Biopharmaceuticals Trading Up 2.1%
NASDAQ XTLB traded up $0.05 on Wednesday, hitting $2.43. 10,464 shares of the company’s stock were exchanged, compared to its average volume of 1,297,269. The stock has a 50-day moving average of $2.59 and a 200-day moving average of $5.45. XTL Biopharmaceuticals has a 52 week low of $2.12 and a 52 week high of $10.28. The stock has a market cap of $5.35 million, a price-to-earnings ratio of -3.80 and a beta of 1.64.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research report on Thursday, April 2nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, XTL Biopharmaceuticals currently has a consensus rating of “Sell”.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
See Also
- Five stocks we like better than XTL Biopharmaceuticals
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
